Educational information only. Not medical advice.
Compare compounds, understand the differences, and explore the original studies behind them.
Research reviewed October 15, 2026. Start with the overview, then explore the evidence and sources.
Stages summarize the study designs available for the identified material in this selection. Human stages require studies in which people received that material; measuring the body’s own peptide or testing a different analogue does not qualify. Controlled studies can measure hormone responses or other biological changes, as well as clinical outcomes. A higher stage can include unsuccessful trials; the adjacent summary explains the findings and limitations.
Multiple reports from one trial count as one study for this classification. The selected-report totals below describe library coverage. Outcome-specific certainty would require a separate assessment of study limitations, consistency, applicability, precision and publication bias.
Synthetic peptide, 15 amino-acid residues
The defined fragment reviewed here is N-acetylated thymosin β4 residues 17–23, also written Ac-LKKTETQ. It has an acetyl group at the start of its seven-amino-acid chain and a free carboxyl end.
Researchers have studied BPC-157 in animal tendon, muscle, ligament and intestinal injury models. Small human reports describe knee pain and bladder symptoms, and an older controlled ulcerative-colitis study was reported in a conference abstract. Human tissue repair and a treatment benefit remain unestablished.
TB-500 research examines detection and metabolism of the acetylated Ac-LKKTETQ fragment, including anti-doping analysis. Tissue-repair research must distinguish this fragment from full-length thymosin β4, unacetylated LKKTETQ and products whose sequence was not reported.
The categories describe the most advanced study designs selected for this library. Each summary explains what was measured and what remains uncertain.
One controlled human study
FDA summarizes an older conference abstract: 53 people with ulcerative colitis were randomly assigned to rectal BPC-157 or placebo. Both groups improved on a colitis-activity score; the treatment-difference confidence interval included zero, leaving benefit unresolved. The full trial report was unavailable. Knee and bladder reports lacked controls. In surgically repaired rat Achilles tendons, four per group were pulled until they broke on day 30. The BPC-157 group had a higher median (middle) breaking force than controls given no peptide, but the comparison was too uncertain to establish an effect.
Animal studies
Animal studies tracked the defined fragment and its breakdown products. A shorter metabolite helped cultured fibroblasts close a gap in their cell layer; the parent fragment did not establish that effect. The rat tendon result used a TB-500-labelled product with unresolved sequence and form. Human eye trials tested full-length thymosin β4, a different peptide. No selected human trial tests this fragment.
Synthetic 15-residue GEPPPGKPADDAGLV; free-base and acetate identities are distinguished.
Defined TB-500 is Ac-LKKTETQ, an acetylated seven-residue fragment. The 2026 tendon paper did not report the peptide sequence of the product it called TB-500.
Researchers cut and surgically repaired the Achilles tendons of 32 rats, then assigned eight rats each to BPC-157, the product identified as TB-500 in the study, both peptides or neither peptide. The rats in the last group received the injection liquid without either peptide; the paper calls this liquid the vehicle but does not specify its composition. Thirty days after surgery, the investigators pulled four repaired tendons from each group until they broke and recorded the force they could withstand.
The tendons from rats given BPC-157 withstood more force than those from rats given neither peptide. The difference was too uncertain to establish an effect of BPC-157 in this small experiment (adjusted P=0.389).
The tendons from rats given TB-500 also withstood more force than those from rats given neither peptide, and this difference met the study's threshold for statistical significance (adjusted P=0.0406). The study did not establish that TB-500 worked better than BPC-157.
Small uncontrolled knee-pain reports include patient-reported improvement after local treatment; they establish no controlled tendon-healing effect.
FDA found no clinical studies of the evaluated fragment. Full-length thymosin beta-4 human studies concern a different material.
The selected intact-peptide study measured rats and dogs after intravenous/intramuscular exposure; it provides no human value.
Human serum laboratory metabolism and animal urine detection do not supply a measured human concentration-time course.
In the 2026 rat study, combining BPC-157 with the product identified as TB-500 did not establish greater repaired-tendon strength than giving either peptide alone. Only four tendons per group were tested.
The rat study did not establish an added strength benefit from combining the peptides. Neither that experiment nor the small uncontrolled human knee series establishes that the combination works better in people.
Human safety observations remain brief and small. Lee and Burgess (2025) followed two adults, both previously exposed to intravenous BPC-157, through 24 hours after a second infusion. They reported no adverse symptoms or clinically significant adverse changes in the collected measurements. FDA's 2026 briefing also describes an older rectal-preparation study with 32 randomized healthy participants, 24 receiving active treatment, and no significant attributable adverse events. Headache and flatulence were the most frequently reported events in the older healthy-volunteer accounts, with no obvious difference from placebo. Sample size, prior exposure and short observation constrain what these reports can reveal about uncommon or delayed harms.
The exact fragment lacks an adequate clinical safety record in the sources reviewed here. A laboratory test found no detectable toxicity in cultured fibroblasts, cells that help build connective tissue, under its tested conditions. It leaves immune reactions, systemic organ effects, uncommon adverse events and longer exposure unresolved.
These are selected reports; several reports can come from one trial or cohort. Counts describe this library’s coverage.
No sections match this focus. Choose All sections to read the full comparison.
Read how the compounds differ, what direct studies found, and which questions remain open.
BPC-157 has been studied in several animal injury models and a few small human reports. Research on the defined acetylated TB-500 fragment is largely analytical or laboratory work. A small 2026 rat study tested BPC-157 alongside a TB-500-labeled preparation, but the paper did not fully identify that preparation or establish a clear difference between the two compounds.
CJC-1295 with DAC was designed to bind albumin and prolong growth-hormone signaling, and early studies measured its persistence and hormone effects in healthy volunteers. Modified GRF(1–29) shares the modified GHRH core but lacks that extension; most selected reports concern chemical identification, leaving much less human pharmacology to compare.
Direct trials found greater average weight and blood-glucose reductions with tirzepatide at the formulations tested. Receptor biology, available products, approved uses, cardiovascular outcomes and tolerability add context when comparing the two medicines.
Liraglutide and semaglutide activate the same GLP-1 receptor. Direct trials found larger average weight and blood-glucose reductions with semaglutide under the protocols tested. The comparison explains those trials, formulation differences, tolerability and separate cardiovascular evidence.
ACHIEVE-3 directly compared oral orforglipron capsules with oral semaglutide tablets in adults with type 2 diabetes taking metformin. Orforglipron lowered average blood glucose more. More participants reported stomach or intestinal adverse events or stopped treatment because of adverse events, and the average pulse increase was larger with orforglipron. The results concern the trial formulations and strengths; weight-management products need separate context.